West Pharmaceutical Services 3Q 2026: Revenue $874.5M, EPS $3.02— 10-Q Summary
West Pharmaceutical Services reported 3Q 2026 revenue of $874.5M, up 8.7% YoY, and net income of $214M, up 52.9% YoY. EPS was $3.02, up 57.3% YoY. Organic sales grew 11.9%, driven by biologics and GLP-1 demand, while West Vantage sales declined 6.6% due to a contract expiration. The company sold its SmartDose 3.5mL product line to AbbVie.
How this was made
The 30-second read
Why it matters
Earnings beat suggests near‑term price appreciation; investors should watch guidance and any forward‑looking commentary in the filing.
Market read
New earnings data for a mid‑cap healthcare supplier, likely to trigger short‑term trading activity.
What to watch
Potential one‑time gain from the SmartDose asset sale to AbbVie may not repeat, and the contract expiration risk in glucose‑monitoring could affect future growth.
Background
The article is a 10‑Q summary from West Pharmaceutical Services (WST) providing its third‑quarter 2026 financials.
Ticker impact
West Pharmaceutical Services disclosed its Q3 2026 results with revenue of $874.5M (+8.7% YoY) and net income of $214M (+52.9% YoY).
likely upside as the market prices in the earnings beat and higher profit margin.
The sizable profit jump and revenue growth are new information that can move the stock immediately.
Market effects
Positive for medical device and pharma packaging sector as demand for biologics and GLP‑1 components rises.
U.S. healthcare equipment market may see modest uplift.
Limited to investors tracking mid‑cap healthcare manufacturers.
Counterpoint
The decline in West Vantage sales and the recent cyber incident could weigh on margins if future disruptions occur.
Key entities
- companyWest Pharmaceutical Services
Medical device and pharmaceutical packaging manufacturer.
- companyAbbVie
Acquirer of West's SmartDose product line.
